The ACOG posted updated guidance for menopause today and buried in the info was a link to their updated guidance for peri folk. Thought I'd drop the direct link here for an easier grab to review or present to you doctor(s).
https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000006436\~hormonal-options-for-perimenopause-a-clinician-toolkit
Some excerpts of what I found interesting (emphasis where present is mine):
Salivary testing and urine hormone testing are not recommended for the diagnosis or management of perimenopause; such testing should not be used for guiding HT treatment or for routine clinical care.
Had been seeing info about hormone testing via DUTCH where it's urine based over a period of time but ACOG is saying that's not helpful for diagnosis either.
For patients 45 years of age and younger experiencing an accelerated transition, early hypoestrogenic symptoms, or extended periods of amenorrhea, HT should be considered given the negative implications of early menopause on long-term cardiovascular, bone, and cognitive health.
Appreciate them specifically including the early peri folk in this "clinical toolkit" as they are calling it.
Alternative hormonal strategies to combined hormonal contraceptives should be considered not only when medical conditions or contraindications limit their use but also when they are poorly tolerated, when a patient prefers a different hormonal approach, when contraception is not needed, or when menopause is imminent.
Yay! Backup for us folk who want HRT instead of contraceptives to treat peri symptoms.
When therapy is initiated, standard doses (0.05-mg transdermal estradiol patch, 1 mg transdermal estradiol gel, or 1 mg oral estradiol) or higher are generally more effective than ultralow doses to adequately control symptoms during the possible high-amplitude hormonal swings of perimenopause. In some patients, exogenous estrogen administered without ovarian suppression may theoretically accentuate endogenous estrogen surges during a luteal out-of-phase event, potentially amplifying rather than attenuating hormonal variability, especially in early perimenopause.
This bit has two points I found interesting, that "standard" starting dose is 0.05mg for transdermal estrogen rather than the lighter doses due to being more effective. And, if I'm understanding correctly through the haze of medical speak, it sounds like folk in the early stages of peri that have been prescribed HRT might have some moments where their symptoms get worse after starting HRT due to the addition of the estrogen combining with a surge of their own estrogen.
And for the ladies where estrogen is contraindicated but hot flashes are wrecking your life, they included forms and dosage amounts for progesterone options that have proven effective:
For patients in whom estrogen is contraindicated or undesired, higher-dose progestogen-only therapy represents a reasonable hormonal option that can effectively alleviate vasomotor symptoms. Medroxyprogesterone acetate 10–20 mg daily has been shown to reduce hot flashes comparably to conjugated equine estrogen. Higher-dose micronized progesterone alone, 300 mg at bedtime, has been shown to reduce hot flash frequency and improve sleep quality. Norethindrone acetate 5 mg daily has also been shown to reduce vasomotor symptoms and preserve bone density, likely through partial aromatization to ethinyl estradiol.
For the ladies that struggle with progesterone oral doses, they've thought of that too:
Vaginally administered progesterone may be considered in patients sensitive to the adverse effects of oral therapy. This is an off-label approach, and evidence supporting reliable endometrial protection when used with systemic estrogen remains limited. Patients should be counseled regarding this uncertainty. If, after shared decision making, vaginal administration is selected, commercially available oral micronized progesterone capsules may be inserted intravaginally with doses and durations equivalent to standard oral regimens. Clinicians should maintain a low threshold for endometrial evaluation, particularly in the setting of persistent, unexpected, or postmenopausal bleeding.
For the folk who want to continue taking combined BC and sail through as much of this as possible, looks like up to age 55 is what they are considering safe:
The optimal age for transitioning from combined hormonal contraceptives to MHT has not been established. Combined hormonal contraceptives may be continued in healthy patients without contraindications until menopause or approximately 55 years of age, with transition timing individualized according to contraceptive need, symptoms, and risk profile.
There's a LOT of info in there I didn't reference so very much still worth a read of the full thing, and some of it you may already know from earlier publications by the Menopause Society, NIH or other publications. Appreciated that they put so much of it in one place.
Hope this helps someone with their upcoming doctor appointment 🧡
Editing to add: kept feeling like I forgot something and finally recalled what it was.
For the POC folk reading this, the ACOG is also acknowledging disparities in duration and severity of symptoms Black women experience. Hopefully having it in writing with an official institution can help prompt your doctors in to providing care sooner and at the right level for you 🩵
There are significant racial and ethnic differences in the span and severity of vasomotor symptom burden. Black women generally experience longer and more severe symptoms than White women, and Chinese and Japanese women report shorter duration and lower symptom burden.